Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study.
Valentina Tuninetti,Eleonora Ghisoni,Sandro Pignata,Elisa Picardo,Francesco Raspagliesi,Claudia Andreetta,Elena Maldi,Grazia Artioli,Serafina Mammoliti, Lucia Zanchi,Angelica Sikokis,Nicoletta Biglia,Alessandro Parisi,Vincenzo Dario Mandato,Claudia Carella,Gennaro Cormio,Marco Marinaccio,Andrea Puppo,Biagio Paolini, Lucia Borsotti,Giulia Scotto,Margherita Turinetto,Dario Sangiolo,Massimo Di Maio,Giorgio Valabrega Annals of Oncology（2023）
摘要
Ki67 at diagnosis did not discriminate responders to PARPi.
更多查看译文
关键词
Ki67,PARP inhibitor,niraparib,ovarian cancer,rucaparib
AI 理解论文
溯源树
样例
